PharmAust Limited (PAA) is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem. PAA’s lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer.
PharmAust Limited belongs to Health Care sector and under industry of Pharmaceuticals. You can get more information about this company via their website: http://www.pharmaust.com.
This a small cap company with market cap of 30 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is less than both sector and market. while On the other hand, Company Earning is less than both sector and market.
Dividend Growth Chart
The following chart shows you how paa dividend grows in the recent years.